AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca New Molecular Entities in late-stage pipeline by Quarter
New Molecular Entities (NMEs) in late-stage pipeline (count)
AstraZeneca New Molecular Entities in late-stage pipeline: 21 in Q2 2026, up 10.5% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
“183 projects in development pipeline | 21 NMEs in late-stage pipeline | 116 NME or major LCM projects in Phase II or Phase III | 29 regulatory approvals in major markets (US, EU, CN, JP)”
Source: Clinical Trials Appendix (2026Q2) ↗
Reported in Clinical Trials Appendix (Pipeline at a glance).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Molecular Entities (NMEs) in late-stage pipeline (count) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 21 | +10.5% | Clinical Trials Appendix (2026Q2) ↗ |
| Q1 2026 | Mar 31, 2026 | 21 | +16.7% | Clinical Trials Appendix (2026Q1) ↗ |
| Q4 2025 | Dec 31, 2025 | 20 | +5.3% | Clinical Trials Appendix (2025Q4) ↗ |
| Q3 2025 | Sep 30, 2025 | 20 | -4.8% | Clinical Trials Appendix (2025Q3) ↗ |
| Q2 2025 | Jun 30, 2025 | 19 | -5.0% | Clinical Trials Appendix (2025Q2) ↗ |
| Q1 2025 | Mar 31, 2025 | 18 | -5.3% | Clinical Trials Appendix (2025Q1) ↗ |
| Q4 2024 | Dec 31, 2024 | 19 | +11.8% | Clinical Trials Appendix (2024Q4) ↗ |
| Q3 2024 | Sep 30, 2024 | 21 | – | Clinical Trials Appendix (2024Q3) ↗ |
| Q2 2024 | Jun 30, 2024 | 20 | – | Clinical Trials Appendix (2024Q2) ↗ |
| Q1 2024 | Mar 31, 2024 | 19 | – | Clinical Trials Appendix (2024Q1) ↗ |
| Q4 2023 | Dec 31, 2023 | 17 | – | Clinical Trials Appendix (2023Q4) ↗ |
Cite this data
StockData. (2026). AstraZeneca New Molecular Entities in late-stage pipeline, quarterly Q4 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cta-late-stage-nmes
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.